Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Combined Temozolomide and Targeted P53 Gene Therapy (SGT-53) for Treatment of Patients With Recurrent Glioblastoma

NCT02340156 is registered in ClinicalTrials.gov with SynerGene Therapeutics, Inc. as lead sponsor.

NCT NCT02340156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02340156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Combined Temozolomide and Targeted P53 Gene Therapy (SGT-53) for Treatment of Patients With Recurrent Glioblastoma
Lead sponsor
SynerGene Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2014
Completion date
November 30, 2018
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma